The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
Open accessAbstract
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HCC risk score to predict the HCC development for patients with chronic hepatitis. METHODS: A total of 17,374 patients, comprising 10,578 treated Asian patients with chronic hepatitis B (CHB), 2,510 treated Caucasian patients with CHB, 3,566 treated patients with hepatitis C virus (including 2,489 patients with cirrhosis achieving a sustained virological response) and 720 patients with non-viral hepatitis (NVH) from 11 international prospective observational cohorts or randomised controlled trials, were divided into a training cohort (3,688 Asian patients with CHB) and 9 validation cohorts with different aetiologies and ethnicities (n = 13,686). RESULTS: We developed an HCC risk score, called the aMAP score (ranging from 0 to 100), that involves only age, male, albumin-bilirubin and platelets. This metric performed excellently in assessing HCC risk not only in patients with hepatitis of different aetiologies, but also in those with different ethnicities (C-index: 0.82-0.87). Cut-off values of 50 and 60 were best for discriminating HCC risk. The 3- or 5-year cumulative incidences of HCC were 0-0.8%, 1.5-4.8%, and 8.1-19.9% in the low- (n = 7,413, 43.6%), medium- (n = 6,529, 38.4%), and high-risk (n = 3,044, 17.9%) groups, respectively. The cut-off value of 50 was associated with a sensitivity of 85.7-100% and a negative predictive value of 99.3-100%. The cut-off value of 60 resulted in a specificity of 56.6-95.8% and a positive predictive value of 6.6-15.7%. CONCLUSIONS: This objective, simple, reliable risk score based on 5 common parameters accurately predicted HCC development, regardless of aetiology and ethnicity, which could help to establish a risk score-guided HCC surveillance strategy worldwide. LAY SUMMARY: In this international collaboration, we developed and externally validated a simple, objective and accurate prognostic tool (called the aMAP score), that involves only age, male, albumin-bilirubin and platelets. The aMAP score (ranged from 0 to 100) satisfactorily predicted the risk of hepatocellular carcinoma (HCC) development among over 17,000 patients with viral and non-viral hepatitis from 11 global prospective studies. Our findings show that the aMAP score had excellent discrimination and calibration in assessing the 5-year HCC risk among all the cohorts irrespective of aetiology and ethnicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H. L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9151 · Cited by 2,783
Self-citation(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-5-642_1 · Cited by 2,081
Yang, H.-I., Yuen, M.-F., Chan, H. L.-Y., Han, K.-H., Chen, P.-J., Kim, D.-Y., Ahn, S.-H., Chen, C.-J., Wong, V. W.-S., & Seto, W.-K. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70077-8 · Cited by 669
Papatheodoridis, G., Dalekos, G., Sypsa, V., Yurdaydin, C., Buti, M., Goulis, J., Calleja, J. L., Chi, H., Manolakopoulos, S., Mangia, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.035 · Cited by 557
Self-citationClinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
Wong, V. W.-S., Chan, S. L., Mo, F., Chan, T.-C., Loong, H. H.-F., Wong, G. L.-H., Lui, Y. Y.-N., Chan, A. T.-C., Sung, J. J.-Y., Yeo, W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2675 · Cited by 502
Agarwal, K., Brunetto, M., Seto, W. K., Lim, Y.-S., Fung, S., Marcellin, P., Ahn, S. H., Izumi, N., Chuang, W., Bae, H., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.039 · Cited by 428
Self-citationPinato, D. J., Sharma, R., Allara, E., Yen, C., Arizumi, T., Kubota, K., Bettinger, D., Jang, J. W., Smirne, C., Kim, Y. W., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.008 · Cited by 413
Wong, G. L.-H., Chan, H. L.-Y., Wong, C. K.-Y., Leung, C., Chan, C. Y., Ho, P. P.-L., Chung, V. C.-Y., Chan, Z. C.-Y., Tse, Y.-K., Chim, A. M.-L., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.029 · Cited by 280
Cited by
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., et al. (2023) · Liver Cancer · doi:10.1159/000530495 · Cited by 477
Self-citationEuropean Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Xie, D., Shi, J., Zhou, J., Fan, J., & Gao, Q. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0402 · Cited by 177
Metadata
- Authors
- Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., Mo, S., Sypsa, V., Guha, I. N., Kumada, T., Niu, J., Dalekos, G., Yasuda, S., Barnes, E., Lian, J., Suri, V., Idilman, R., Barclay, S. T., Dou, X., Berg, T., Hayes, P. C., Flaherty, J. F., Zhou, Y., Zhang, Z., Buti, M., Hutchinson, S. J., Guo, Y., Calleja, J. L., Lin, L., Zhao, L., Chen, Y., Janssen, H. L. A., Zhu, C., Shi, L., Tang, X., Gaggar, A., Wei, L., Jia, J., Irving, W. L., Johnson, P. J., Lampertico, P., & Hou, J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 73
- Issue
- 6
- Pages
- 1368-1378
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3044553904
- Cited by
- 364
- References
- 21
- FWCI
- 19.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. https://app.cochat.ai/papers/10.1016/j.jhep.2020.07.025
- The paper
- Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., Mo, S., Sypsa, V., Guha, I. N., Kumada, T., Niu, J., Dalekos, G., Yasuda, S., Barnes, E., Lian, J., Suri, V., Idilman, R., Barclay, S. T., Dou, X., . . . Hou, J. (2020). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2020.07.025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.